This morning, Roche announced the headline results of their Ocrelizumab
in relapsing MS program (OPERA I and II). Here is their press release:
Numerous posts on this blog have highlighted the potential of this humanized version of Rituximab (check the "BartsMS essential off-label DMT list" in the left upper corner), an
established drug to treat people with B cell lymphoma, for the treatment of people with MS. Ocrelizumab appears to be significantly better compared to interferon beta, however is it as good as alemtuzumab but without the significant risk of autoimmunity?